Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Conventional Anti-Atherosclerosis Therapy

Preclinical

XXiangya Hospital of Central South University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Carotid Artery PlaqueNot yet recruiting

Carotid Artery PlaquePreclinical

Not yet recruiting

Timeline

Expected Milestones

Q1 2029

PreclinicalNot yet recruiting

Carotid Artery Plaque

NCT07840950

Clinical

Trials by Indication[1]

Carotid Artery Plaque1 trial

Mechanism of Action and Real-World Study of Rosa Roxburghii Tratt Freeze-Dried Juice Powder and Its Extracts Against Carotid Atherosclerotic Plaques

Not yet recruiting·XXiangya Hospital of Central South University·Preclinical·NCT07840950·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Conventional Anti-Atherosclerosis Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Conventional Anti-Atherosclerosis Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Xiangya Hospital of Central South University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: XXiangya Hospital of Central South University

Related News